Spartalizumab

Spartalizumab (INN;[1] development code PDR001) is a monoclonal antibody that is being investigated for melanoma.

Spartalizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized
TargetPDCD1, CD279
Clinical data
Other namesPDR001
ATC code
  • none
Identifiers
CAS Number
KEGG

This drug is being developed by Novartis. As of 2018, spartalizumab is undergoing Phase III trials.

References

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.